FluroTech's CompleTest™ Makes Cannabis Testing More

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
47
FluroTech's CompleTest™ Makes Cannabis Testing More Accessible -- CFN Media

SEATTLE, Feb. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing  FluroTech Ltd.  (TSX-V: TEST) (OTCQB: FLURF). The company has developed the industry's most affordable, accurate, portable, and easy-to-use cannabis testing device to solve testing issues. After securing final certifications, the device is ready for imminent commercialization, creating an early-stage opportunity for investors.

The market for cannabis testing is projected to be $300 million in Canada, $750 million in the United States, and $2.75 billion worldwide. Despite the market size and tremendous need, most cannabis testing solutions are both expensive and unreliable. Cultivators struggle to optimize yields and contain infestations, while consumers have faced recalls for both contamination and mislabeling on a regular basis.

Cannabis Testing Challenges

Traditional agriculture, food, and beverage industries must adhere to regulations governing everything from crop pesticides to language on labels. Since cannabis remains illegal in many countries, traditional governing bodies can’t exercise control over the production and sales of flower, edibles, oils, and other cannabis derivatives. These dynamics have created significant challenges for governments, cultivators, dispensaries, and consumers.

Even in federally-regulated markets, like Canada, there have been many quality control issues within the cannabis industry. Some products were contaminated with banned pesticides, heavy metals, or mold, while others were mis-labeled with the wrong cannabinoid content information. These problems put consumers at risk of falling ill and cannabis businesses at risk of damaging their brand reputation.

Most cannabis testing equipment is very expensive, making it unaffordable for small cannabis companies. For example, mass spectrometry devices cost upwards of $1 million with a three to 14 day turnaround time for results. High performance chromatography is less expensive at just $250,000 per device and has a much smaller footprint, but it still requires highly-trained operators and takes ten to 14 days to turnaround a single test result.

Please Click here to Download FluroTech Ltd's Investor Presentation

CompleTest™ Improves Accessibility

FluroTech’s CompleTest™ was designed from the ground up to be the most cost-effective, portable, and easy-to-use solution on the market, providing consistent results in minutes rather than days or weeks. Minimally-trained operators can simply extract a small portion of dried, ground cannabis bud, mix the sample with the test kit reagent, insert the sample into the device, and receive highly-accurate test results on a smartphone or tablet in minutes.

There are many benefits to having these testing capabilities in-house:

  • Early Detection:  Cultivators can immediately detect early contamination in a grow cycle, purge the grow room, and rapidly return it back to production. In addition, external cannabis supply can be tested before extraction processes.
  • Optimization:  Cultivators can quickly test different strategies for optimizing harvest time or product quality. For example, growers using CompleTest™ recently found that different lighting solutions improved potency by 50 percent.

It’s difficult to overstate these benefits for cultivators. In Canada, many licensed producers model a one percent increase in potency leading to an additional 80 cents per gram in selling price. A one percent increase in potency in exchange for a $20,000 capital outlay results in a payback period after just 25 kilograms of dried flower. The effect of potency on selling price is amplified even more for cultivators that are focused on extraction end markets.

Commercialization Phase

FluroTech just began to commercialize CompleTest™ in early February after securing Canadian Standards Association (CSA) and Underwriters Laboratories (UL) product safety certification for North America. Prior to the certifications, the company had also showcased the device at the Lift Expo in Vancouver, where it received positive feedback from attendees that could signal early interest in sales of the device.

“We have completed the design verification, testing, and certification of CompleTest™ and are excited to launch into a high growth market,” said FluroTech VP of Business Development Gary Jones. “The CompleTest™ was unveiled to master growers and quality assurance personnel at the recent Lift Expo in Vancouver, where over 60 live demonstrations were completed demonstrating the capabilities of our device.”

Please Click here to Download FluroTech Ltd's Investor Presentation

The CompleTest™ generates revenue from these sources:

  • CompleTest™ Unit:  The actual unit sells for $18,000
  • CompleTest™ Scopes:  Scopes are used to test for THCA/CBDA potency, heavy metals, mold, and banned pesticides. The THCA & CBDA scopes are $6,000 as is the heavy metal scope.
  • CompleTest™ Test Kit:  Test kits are required for each sample cartridge, providing the necessary reagent for the process. Each test kit costs $60 to $75 with 30 to 50 required per month.

Based on the average cost of each revenue stream, the company would generate with each device sold, $50,000 in the first year and $20,000 per subsequent year per customer. These recurring, high-margin revenue streams resulting from high margin sales exceeding 200 percent in all aspects of the product line could unlock significant value for shareholders over time.

The Bottom Line

FluroTech Ltd.  (TSX-V: TEST) (OTCQB: FLURF) represents a near-term opportunity to capitalize on the growing demand for affordable cannabis testing. In addition to these near-term end markets, management’s long-term plans position the company as a front-runner for saliva-based roadside testing, industrial testing, and bio-marking, all of which could add billions more in long-term market potential.

For more information, visit the  company’s website

Please Click here to Download FluroTech Ltd's Investor Presentation

Please follow the link to read the full article:

https://www.cannabisfn.com/flurotechs-complet...ccessible/

About CFN Media

CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in the US and Canada have relied on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur:  http://www.cannabisfn.com/featuredcompany

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:  https://itunes.apple.com/us/app/cannabisfn/id...1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:  http://www.cannabisfn.com

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on  http://www.cannabisfn.com  (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.  

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation:  http://www.cannabisfn.com/legal-disclaimer/

Frank Lane 206-369-7050 Flane@cannabisfn.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 170

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 108

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 358

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 336

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 364

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 86

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 372

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 64

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyzing Trump's Executive Orders and Their Economic Impact

Updated Category News Views 806

Executive Orders: A Shift in Economic Paradigms President Trump has taken significant steps by issuing a number of executive orders that have raised eyebrows among economists and market analysts alike. According to market expert Louis Navellier, this approach can be characterized as 'shock and awe'. It reflects a bold strategy that could reshape various aspects of the...

Continue Reading
B2PRIME Expands Institutional Reach with Stuart Brock's Addition

Updated Category News Views 173

B2PRIME Welcomes Stuart Brock as Institutional Business Development Manager B2PRIME Group, a leading financial services provider for institutional and professional clients, recently announced the appointment of Stuart Brock as its Institutional Business Development Manager. With over 15 years of experience in electronic trading and institutional sales, Stuart is poised to...

Continue Reading
United Parks & Resorts Inc. Shares Q1 2025 Financial Insights

Updated Category News Views 374

Financial Overview of United Parks & Resorts Inc. United Parks & Resorts Inc. (NYSE: PRKS), a prominent player in the theme park and entertainment sector, has recently shared its financial results for the first quarter of 2025. This report delves into the key metrics and operational insights that define the company’s performance in this period. Attendance and Revenue...

Continue Reading
Seongnam Pavilion Sets New Benchmark at CES 2025 with 41 Companies

Updated Category News Views 178

Seongnam Pavilion Makes Waves at CES 2025 At the latest CES 2025, Seongnam City showcased an impressive turnout at the world's leading consumer electronics exhibition. This year, Seongnam participated with a remarkable delegation of 41 companies, marking the largest participation ever. Focused on enhancing their global footprint, these small and medium-sized enterprises...

Continue Reading
Gaucho Holdings Seizes Opportunities Amid Argentina's Economic Revival

Updated Category News Views 179

Gaucho Holdings and the New Economic Landscape in Argentina Recently, Argentina has entered a new chapter of economic transformation. A shift in leadership, with Javier Milei becoming president, has sparked hopes for fiscal discipline, growth, and development. As the country embraces pro-market reforms, Gaucho Group Holdings, Inc. (NASDAQ: VINO) positions itself to...

Continue Reading